SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-052298
Filing Date
2018-09-26
Accepted
2018-09-26 16:44:52
Documents
2
Period of Report
2018-09-26

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3645
2 POA DOCUMENT poa.txt EX-24.3_810843 3960
  Complete submission text file 0001209191-18-052298.txt   9002
Mailing Address 5151 CALIFORNIA AVENUE SUITE 250 IRVINE CA 92617
Business Address 5151 CALIFORNIA AVENUE SUITE 250 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Issuer) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O UROVANT SCIENCES, INC. 5151 CALIFORNIA AVENUE, SUITE 250 IRVINE CA 92617
Business Address
Ebersole Nori (Reporting) CIK: 0001748293 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38667 | Film No.: 181088358